ABB
8.4.2021 06:48:04 CEST | Business Wire | Press release
ABB will launch on April 9, 2021 its previously announced follow-up share buyback program of up to $4.3 billion. Based on the current share price this represents a maximum of approximately 137 million shares. The maximum number of shares that may be repurchased under this new program on any given trading day is 1,543,644.
This follow-up program is part of ABB’s plan to return $7.8 billion of cash proceeds from the Power Grids divestment to shareholders and is consistent with the company’s capital structure optimization program. As announced previously, under the initial program ABB repurchased a total of 128,620,589 shares – equivalent to 5.93 percent of its issued share capital at the launch of the program – for a total amount of approximately $3.5 billion. ABB shareholders approved the cancellation of 115 million of these shares at ABB’s 2021 Annual General Meeting (AGM).
The total number of ABB’s issued shares is 2,168,148,264 including the shares approved for cancellation at ABB’s 2021 AGM. ABB currently owns 143,988,616 treasury shares.
The follow-up share buyback program is for capital reduction purposes and will be executed on a second trading line on the SIX Swiss Exchange (Valor: 35.767.961; ISIN: CH035 767 961 9). It is planned to run from April 9, 2021 until March 23, 2022. At the company’s AGM on March 24, 2022, ABB intends to request shareholder approval to cancel the shares purchased through this program as well as those shares purchased under the initial program that were not proposed for cancellation at ABB’s 2021 AGM.
The share buyback program will be managed by a bank mandated by ABB that will make its trading decisions concerning the timing of share repurchases independently of ABB, within pre-agreed parameters. ABB can change these parameters outside of its closed periods and if it is not in possession of any inside information.
The purchase price per share will not exceed the higher of the price of the last independent trade on the ordinary trading line on the SIX Swiss Exchange and the highest current independent bid price on the ordinary trading line on the SIX Swiss Exchange. In addition, customary spreads on purchases on the second trading line on the SIX Swiss Exchange will be paid, observing the limitations of the Ordinance on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading (FMIO). Payment for the shares will be made in cash.
The buyback program is being carried out in accordance with the Ordinance on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading (FMIO), the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052. Weekly updates on the program will be published on ABB’s investor relations website at https://global.abb/group/en/investors/investor-and-shareholder-resources and issued by press release.
ABB (ABBN: SIX Swiss Ex) is a leading global technology company that energizes the transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to drive performance to new levels. With a history of excellence stretching back more than 130 years, ABB’s success is driven by about 105,000 talented employees in over 100 countries. www.abb.com
Important notice about forward-looking information
This press release includes forward-looking information and statements concerning the share buyback program. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance, and are generally identifiable by statements containing words such as “intends”, “expects,” “plans”, or similar expressions. However, there are many risks and uncertainties, many of which are beyond our control, that could affect our ability to achieve any or all of our stated targets. Factors that could cause such differences include, among others, business risks associated with the volatile global economic environment and political conditions, changes in governmental regulations and currency exchange rates and such other factors as may be discussed from time to time in ABB Ltd’s filings with the U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407006050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 15:00:00 CET | Press release
The collaboration combines Tigo software with Google’s Gemini models on Google Cloud to help automate installer and utility operations for distributed energy portfolios. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more custo
Patsnap Releases State of Pharma Intelligence 2026 Report, Reveals Pharma's Cautious Embrace of AI in Decision-Making12.11.2026 15:00:00 CET | Press release
A new survey of 130 senior life sciences leaders on AI in pharma R&D and competitive intelligence finds that 92% can name a recent R&D, portfolio, or partnership decision where AI changed the outcome. Patsnap, the AI-native innovation intelligence company for IP and R&D teams, today released "State of Pharma Intelligence 2026: The Confidence to Act", a benchmark report on how pharma teams use and trust AI in R&D, competitive intelligence and business development decisions. The report draws on responses from 130 senior leaders at Director level or above across the United States, the United Kingdom, Germany, Switzerland, and France, spanning drug developers, CDMOs/CMOs, CROs, and consulting and professional services firms. The survey was fielded in August 2026 in partnership with NewtonX. Patsnap commissioned the research to understand how AI is influencing decisions across pharma R&D and business development, what builds confidence in its output, and where intelligence workflows fall sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
